Biopolymer Delivery of Synergistic Immunotherapy Could Improve Efficacy

Share this content:
CAR T cell therapy is frequently less effective in solid tumors.
CAR T cell therapy is frequently less effective in solid tumors.

Biopolymer codelivery of cells programmed to express chimeric antigen receptors (CAR T cells) and stimulator of IFN genes (STING) directly to the surface of solid tumors reduced tumor size and rates of metastasis more than systemic delivery, according to results of a study using mouse models of pancreatic cancer and melanoma.

STING agonists stimulate immune responses such that CAR T cells are more likely to recognize tumor, limiting the likelihood of escape variants developing.

Immunotherapy using CAR T cells has improved treatment of many hematologic malignancies, but CAR T cell therapy is frequently less effective in solid tumors. This effect is due, in part, to the solid tumor microenvironment being immunosuppressive and, therefore, inactivates T cell responses.

In addition, phenotypic variation characterizes solid tumors such that not all tumor cells express proteins that a given immunotherapy targets. This can allow escape variants that evade CAR T cell targeting to form.

This study first examined implanted biopolymer devices to administer CAR T cells directly to the surfaces of solid tumors in mouse models of pancreatic cancer and melanoma. Results indicated CAR T cells could move from the biopolymers to the tumors to decrease tumor size more than systemic delivery of CAR T cells.

Next, researchers used the biopolymer devices to simultaneously deliver CAR T cells and STING agonists. This co-delivery worked synergistically to stimulate CAR T cells to eradicate even more tumor cells and to limit the formation of escape variants.

Using the biopolymer alone with CAR T cells and together with CAR T cells and STING agonists improved the efficacy of CAR T cell therapy in these mouse models.


1. Smith TT, Moffett HF, Stephan SB, et al. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors [published online April 24, 2017]. J Clin Invest. doi: 10.1172/JCI87624

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs